Pharmafile Logo

News:

September 1, 2021 | COVID, COVID-19, therapy watch, trackers 

Therapy Watch COVID-19 tracker

Find out more about our latest tracking study into COVID-19. This multi-country study will report on hospitalised and non-hospitalised patients across core global markets.

Read more here: https://bit.ly/3mScRpV

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Interactive: Best Behaviour

Download our curated collection of case studies and other useful resources that illustrate how we apply the principles of behavioural science in our research design.

RP Investigates – Q&A session: Living with Lupus

In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.

Webcast: Demand Assessment

Find out how a study design which better reflects real-world choices can produce a more realistic model for the future market.

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Report: Mexico’s drug market access landscape shake-up: What does it mean for pharma?

Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.

Webcast: Virtual Q&A session – The future of digital health

In this webcast, Senior Director, Richard Head and Director of The Medical Futurist, Dr. Bertalan Mesko host a live virtual Q&A discussion about the future of digital health.

Research Partnership is on the rise

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

What does the future hold for Light-chain Amyloidosis?

Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...